Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David G Denardo

Showing results (61-70 of 101) with videos related to

Pageof 11
Sort By:
Immunity|September 21, 2017
Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor ProgressionYu Zhu, John M Herndon, Dorothy K Sojka, et al.
Nature Communications|March 30, 2018
Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillanceMelissa A Meyer, John M Baer, Brett L Knolhoff, et al.
Immunity|August 17, 2017
Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor ProgressionYu Zhu, John M Herndon, Dorothy K Sojka, et al.
Gut|December 3, 2017
Targeting both tumour-associated CXCR2<sup>+</sup> neutrophils and CCR2<sup>+</sup> macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinomaTimothy M Nywening, Brian A Belt, Darren R Cullinan, et al.
Molecular Cancer|February 7, 2026
Therapeutic reprogramming of tumour-associated macrophages in pancreatic cancer using a cytotoxic CCR2-targeted nanotheranosticVikas Kumar Somani, Xiaohui Zhang, Timothy Hung-Po Chen, et al.
Science Translational Medicine|July 5, 2019
Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapiesRoheena Z Panni, John M Herndon, Chong Zuo, et al.
Cancer Immunology Research|May 25, 2023
Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic CancerC Alston James, John M Baer, Chong Zou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2013
Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axisDominic E Sanford, Brian A Belt, Roheena Z Panni, et al.
Journal of Cancer Therapy|October 4, 2013
A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal AdenocarcinomaDominic E Sanford, Matthew R Porembka, Roheena Z Panni, et al.
Cancer Discovery|April 29, 2024
Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic CancerJad I Belle, Devashish Sen, John M Baer, et al.
Pageof 11

Showing results (61-70 of 101) with videos related to

Sort By:
Pageof 11
Immunity|September 21, 2017
Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor ProgressionYu Zhu, John M Herndon, Dorothy K Sojka, et al.
Nature Communications|March 30, 2018
Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillanceMelissa A Meyer, John M Baer, Brett L Knolhoff, et al.
Immunity|August 17, 2017
Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor ProgressionYu Zhu, John M Herndon, Dorothy K Sojka, et al.
Gut|December 3, 2017
Targeting both tumour-associated CXCR2<sup>+</sup> neutrophils and CCR2<sup>+</sup> macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinomaTimothy M Nywening, Brian A Belt, Darren R Cullinan, et al.
Molecular Cancer|February 7, 2026
Therapeutic reprogramming of tumour-associated macrophages in pancreatic cancer using a cytotoxic CCR2-targeted nanotheranosticVikas Kumar Somani, Xiaohui Zhang, Timothy Hung-Po Chen, et al.
Science Translational Medicine|July 5, 2019
Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapiesRoheena Z Panni, John M Herndon, Chong Zuo, et al.
Cancer Immunology Research|May 25, 2023
Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic CancerC Alston James, John M Baer, Chong Zou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2013
Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axisDominic E Sanford, Brian A Belt, Roheena Z Panni, et al.
Journal of Cancer Therapy|October 4, 2013
A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal AdenocarcinomaDominic E Sanford, Matthew R Porembka, Roheena Z Panni, et al.
Cancer Discovery|April 29, 2024
Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic CancerJad I Belle, Devashish Sen, John M Baer, et al.
Pageof 11